Observational study;
Bevacizumab, Radiotherapy and Temozolomide Safety study
in resected and irresectable primary GBM patients.

Median survival for patients with a newly diagnosed GBM is 12.1 months after resection of the tumor to the maximum extent, followed by 60 Gy irradiation in 30 x 2 Gy fractions. Maximal surgical resection is not feasible in a sub-group of patients due to the localization of their tumor, resulting in poorer prognosis. In a selected group of patients the median survival was 14.6 months when resection was followed by radiotherapy in combination with temozolomide during and thereafter temozolomide 6 monthly cycles. Chemoradiotherapy with temozolomide is the current standard treatment for GBM in our center. New combination treatments are required to lengthen survival of GBM patients. This trial utilizes the anti-edema effect of bevacizumab and its vascular normalization response to enhance the efficacy of chemoradiotherapy in resected and irresectable primary GBM patients.

Hypothesis in this trial is safe enhancement of the efficacy of chemoradiotherapy in resected and irresectable primary GBM patients, by using the anti-edema effect of bevacizumab and its vascular normalization response.

N/A

Study population will be treated with standard GBM chemoradiotherapy schedule plus additional 3 infusions of the angiogenesis inhibitor bevacizumab at a dose of 10 mg/kg during irradiation (e.g. one dose every 2 weeks during 6 weeks radiotherapy).